New Results
TPR1, a novel rifampin derivative demonstrates efficacy alone and in combination with doxycycline against the NIAID Category A Priority Pathogen F. tularensis
Jason E. Cummings, Keaton W. Slayden, Richard A. Slayden
doi: https://doi.org/10.1101/2021.02.12.431005
Jason E. Cummings
Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado
Keaton W. Slayden
Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado
Richard A. Slayden
Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado
Article usage
Posted February 13, 2021.
TPR1, a novel rifampin derivative demonstrates efficacy alone and in combination with doxycycline against the NIAID Category A Priority Pathogen F. tularensis
Jason E. Cummings, Keaton W. Slayden, Richard A. Slayden
bioRxiv 2021.02.12.431005; doi: https://doi.org/10.1101/2021.02.12.431005
Subject Area
Subject Areas
- Biochemistry (11745)
- Bioengineering (8751)
- Bioinformatics (29195)
- Biophysics (14971)
- Cancer Biology (12095)
- Cell Biology (17411)
- Clinical Trials (138)
- Developmental Biology (9421)
- Ecology (14179)
- Epidemiology (2067)
- Evolutionary Biology (18306)
- Genetics (12245)
- Genomics (16802)
- Immunology (11867)
- Microbiology (28083)
- Molecular Biology (11592)
- Neuroscience (60965)
- Paleontology (451)
- Pathology (1870)
- Pharmacology and Toxicology (3238)
- Physiology (4959)
- Plant Biology (10427)
- Synthetic Biology (2885)
- Systems Biology (7339)
- Zoology (1651)